{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"IMCODE 003","nct_id":"NCT05968326","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imcode-003-nct05968326. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IMCODE003","arms":[{"description":"Participants will receive autogene cevumeran, atezolizumab and mFOLFIRINOX.","label":"Arm 1: Autogene Cevumeran + Atezolizumab + mFOLFIRINOX","type":"EXPERIMENTAL"},{"description":"Participants will receive mFOLFIRINOX.","label":"Arm 2: mFOLFIRINOX","type":"ACTIVE_COMPARATOR"}],"collaborators":["BioNTech SE"],"completion_date":{"date":"2031-01-01","type":"ESTIMATED"},"conditions":["Adenocarcinoma, Pancreatic Ductal"],"enrollment":{"count":260,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Autogene cevumeran","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"mFOLFIRINOX","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-09","lead_sponsor":"Genentech, Inc.","official_title":"A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2031-01-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease Free Survival (DFS)","timeFrame":"From randomization to first recurrence of PDAC or first occurrence of new cancer, as determined by the investigator, or death from any cause (whichever occurs first), up to approximately 6 years"}],"references":[],"start_date":{"date":"2023-10-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","url":"https://clinicaltrials.gov/study/NCT05968326"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imcode-003-nct05968326"}